Benchmark lowered the firm’s price target on Repligen to $210 from $230 and keeps a Buy rating on the shares. The company reported as-expected results for Q1, but also lowered expectations for 2023 due to slow order recovery and softness in China demand, notes the firm, which cites lower revenues and valuations for comparable stocks for its decreased target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RGEN:
- Repligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
- Repligen sees lowers 2023 adjusted EPS $2.35-$2.42 from $2.61-$2.69
- Repligen reports Q1 adjusted EPS 64c, consensus 59c
- RGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Repligen to Report First Quarter 2023 Financial Results